Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial

IMPORTANCE: Confirmation of long-term comparability between subcutaneous and intravenous trastuzumab is essential. OBJECTIVE: To evaluate efficacy and safety of subcutaneous trastuzumab compared with that of intravenous trastuzumab for patients with ERBB2 (HER2)–positive early breast cancer after 6...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:JAMA Oncol
Autores principales: Jackisch, Christian, Stroyakovskiy, Daniil, Pivot, Xavier, Ahn, Jin Seok, Melichar, Bohuslav, Chen, Shin-Cheh, Meyenberg, Christoph, Al-Sakaff, Nedal, Heinzmann, Dominik, Hegg, Roberto
Formato: Artigo
Lenguaje:Inglês
Publicado: American Medical Association 2019
Materias:
Brief Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512301/
https://ncbi.nlm.nih.gov/pubmed/30998824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.0339
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares